Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Revenue of Marksans Pharma Limited (MARKSANS.NS)
Revenue in 2023 (TTM): $258.98 M
According to Marksans Pharma Limited's latest financial reports the company's current revenue (TTM) is $258.98 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Marksans Pharma Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $258.98 M | $91.75 M | $54.54 M | $50.37 M | $37.31 M |
| 2022 | $220.29 M | $110.71 M | $47.41 M | $40.16 M | $31.67 M |
| 2021 | $176.05 M | $87.08 M | $35.04 M | $29.44 M | $21.95 M |
| 2020 | $162.75 M | $89.18 M | $42.15 M | $35.94 M | $28.37 M |
| 2019 | $134.32 M | $66.73 M | $22.46 M | $18.69 M | $14.36 M |
| 2018 | $117.43 M | $55.88 M | $15.8 M | $12.41 M | $9.57 M |
| 2017 | $108.56 M | $43.35 M | $9.89 M | $5.92 M | $3.92 M |
| 2016 | $91.25 M | $35.1 M | $5.89 M | $1.85 M | $1.13 M |
| 2015 | $106.25 M | $45.63 M | $16.8 M | $12.71 M | $9.34 M |
| 2014 | $94.76 M | $41.78 M | $21.49 M | $18.54 M | $13.01 M |
| 2013 | $74.93 M | $31.17 M | $14.01 M | $10.28 M | $8.55 M |
| 2012 | $52.15 M | $22.07 M | $8.36 M | $5.18 M | $5.46 M |
| 2011 | $42.29 M | $16.96 M | $-11,623,836 | $-20,814,958 | $-21,271,231 |
| 2010 | $36.31 M | $8.06 M | $-600,202 | $-25,624,928 | $-26,552,737 |
| 2009 | $42.74 M | $7.75 M | $3.05 M | $-1,097,409 | $-1,194,566 |
| 2008 | $42.83 M | $8.74 M | $3.56 M | $-832,485 | $-993,791 |
| 2007 | $31.39 M | $7.58 M | $4.96 M | $2.44 M | $1.87 M |
| 2006 | $28.78 M | $5.38 M | $3.35 M | $1.11 M | $796.07 K |
| 2005 | $35.37 M | $8.12 M | $5.42 M | $3.74 M | $2.72 M |
| 2004 | $30.08 M | $7.64 M | $4.58 M | $2.98 M | $2.45 M |